UK-BNO-230019. DOP: January 2023.
Resources
For healthcare professionals
Post-Stroke Spasticity Risk Classification System
This risk classification system has been developed by a panel of international experts in PSS and AbbVie. This tool is designed to support healthcare professionals when evaluating patients who have had a stroke, ideally within the first 12 weeks post-stroke and recommended to be used at regular follow-up visits too.
This screening tool provides information on the criteria that determine whether post-stroke patients receive an urgent referral, routine referral or periodic monitoring and includes the next steps that should be considered.
To receive a copy of this risk classification system, please submit your details on the Contact Us page and tick Post-Stroke Spasticity Risk Classification System.
Post-stroke Spasticity Early Identification Guide
This guide is for healthcare professionals who manage stroke patients who may be at risk of developing PSS or who have PSS.
This guide contains information about the prevalence of PSS, the impact of PSS on patients’ lives, the risk factors that may contribute to the development of PSS and most importantly highlighting the importance of early identification of these patients to avoid worsening of untreated spasticity as supported by the Royal College of Physicians National Guidelines 2018.
To receive a copy of this guide, please submit your details on the Contact Us page and tick Post-stroke Spasticity Early Identification Guide.
For your patients
A guide for patients being treated with BOTOX® (Botulinum toxin type A) for post-stroke spasticity
To support your patients with PSS that have been prescribed BOTOX®, this guide provides information on how BOTOX® works, what patients can expect during and after treatment and any potential side-effects of BOTOX® treatment.
The information in this guide does not replace with Patient Information Leaflet that is included with the prescribed medication.
To receive a copy of this guide, please submit your details on the Contact Us page and tick A guide for patients being treated with BOTOX® (Botulinum toxin type A) for post-stroke spasticity.
PSS: post-stroke spasticity.
BOTOX® (botulinum toxin type A) is indicated for the treatment of focal spasticity including:5
- wrist and hand disability due to upper limb spasticity associated with stroke in adults
- ankle and foot disability due to lower limb spasticity associated with stroke in adults
References
- Allergan. Data on file. INT/0423/2016
- Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
- Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
- Allergan. Data on file. 014
- BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed January 2023
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.
Date of preparation: January 2023. UK-BTX-220211.
